Russia Launches First Domestic HPV Vaccine Amid Limited Public Awareness

Russia began producing its first domestic HPV vaccine in autumn 2025. The vaccine, now approved for adults and children aged nine and above, marks a step forward in public health efforts. Yet, little information exists on how widely it has been adopted or promoted across the country. The Kirov Region became home to Russia's first HPV vaccine production site in late 2025. Since then, the vaccine has received authorisation for use in adults and, as of January 2026, for children from the age of nine. Officials plan to include it in the National Immunization Schedule once production increases.

HPV remains widespread, with up to 80-90% of people in the Nizhny Novgorod Region contracting the virus at some point. Most infections—around 90%—show no symptoms and clear naturally. Detection relies solely on PCR testing, as mass screening is not yet available. Health professionals stress the importance of prevention, particularly childhood vaccination. They also call for better public awareness campaigns to inform residents about the virus and protective measures.

The domestic HPV vaccine is now available, but its impact remains unclear due to limited data on vaccination rates or public outreach. With no mass screening in place, PCR testing stays the only way to confirm infections. Officials expect wider vaccine distribution once production scales up further.